Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Integrated DNA Technologies Launches its First Cancer Panel

Published: Friday, October 25, 2013
Last Updated: Friday, October 25, 2013
Bookmark and Share
Fast and accurate screening for mutations identified in acute myeloid lymphoma using the xGen® Acute Myeloid Lymphoma Panel v1.0.

Integrated DNA Technologies (IDT) is enabling cancer research with its latest next generation sequencing (NGS) product, the xGen® Acute Myeloid Leukemia Cancer Panel v1.0.

Consisting of 11,743 xGen Lockdown® Probes, this cancer panel targets over 260 clinically relevant genes that were found to be mutated in a study of 200 patients with acute myeloid leukemia (AML), and published by The Cancer Genome Atlas consortium.

The AML Cancer Panel is used for enriching the genome for regions of interest before performing NGS. It can, therefore, be used to study disease occurrence and progression, and help with the development of better targeted therapies.

Target enrichment enables users to focus their sequencing efforts on specific regions of the genome, providing a cost-effective and reliable alternative to whole genome sequencing, making NGS more accessible to researchers.

By including only relevant xGen Lockdown Probes, the AML Cancer Panel enables high coverage of targeted regions, with minimal GC bias.

As cancer is a genetic disease driven by both heritable and somatic mutations, NGS technologies can significantly improve its detection, management, and treatment.

DNA from a patient could be enriched for these AML-related genes using capture panels such as the xGen AML Cancer Panel and sequenced to identify mutated genes. Subsequently, the patient would receive therapy specific to their cancer profile.

Periodic sequencing of these genes would allow monitoring of disease progression for both research and clinical purposes. As such, more tailored therapies can be developed and a personalized treatment regimen can be implemented.

Ibrahim Jivanjee, Product Manager for NGS at IDT, commented, “We have invested a significant amount of resources into the development of our xGen product line, and are delighted to see such success from these products already. The launch of our first cancer panel has been a significant milestone, with early collaborators demonstrating its potential for use in patient diagnosis and monitoring.”

He continued, “With next gen sequencing becoming an increasingly prominent technique within cancer diagnosis and personalized medicine, IDT, with its leading position in oligonucleotide technology will continue to be at the forefront of developments in this rapidly advancing field.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Discover the Latest NGS-Based Assays Guiding Precision Oncology
IDT joins forces with Foundation Medicine in AMP workshop.
Saturday, November 08, 2014
IDT Acquires SURVEYOR® Nuclease Business from Transgenomic
Addition of SURVEYOR enzyme and kits expands IDT's molecular biology product offerings.
Wednesday, July 02, 2014
Providing a Rapid and Reliable Method of Gene Cloning
Integrated DNA Technologies will be speaking at the upcoming Antibody Engineering and Therapeutics conference.
Monday, December 02, 2013
Webinar: the Cutting-edge qPCR Approach to Single-cell Expression Profiling
Join IDT and Professor Mikael Kubista for insight into pioneering qPCR methods, June 25.
Monday, June 24, 2013
IDT Launches Michael Zuker’s UNAFold Page
UNAFold secondary structure prediction software to be used to accurately detect secondary structures within sequences submitted by customers.
Thursday, December 02, 2010
IDT Presents at Presidential Commission for the Study of Bioethical Issues
Representing the International Gene Synthesis Consortium and its ongoing work to prevent the misuse of synthetic genes.
Tuesday, September 21, 2010
IDT is Awarded Further Funding for Gene Silencing Research
Company receives a Phase II SIBR grant to fund the ongoing ‘Gene Silencing with U1 Adapter Oligonucleotides’ research project.
Thursday, July 22, 2010
IDT Earns ISO 9001:2008 Certification at its European Oligonucleotide Production Headquarters
Worldwide certification of quality systems at all manufacturing operations completed.
Tuesday, April 27, 2010
Integrated DNA Technologies and Glycon Partner in Australia
Glycon will offer Australia’s scientists local sales and technical support of IDT’s products, complementing IDT’s existing global customer care network.
Monday, April 19, 2010
IDT Secures Funding for new Gene Silencing Research
IDT has been awarded $99,750 from NIH to continue work on its ‘Gene Silencing with U1 Adapter Oligonucleotides’ research project.
Monday, September 07, 2009
Major International Conferences to Hear About the Risks and Rewards of Synthetic Biology
IDT will be presenting recent developments in RNAi research, at Analytica and the RNAi World Congress.
Wednesday, March 19, 2008
IDT Acquires Belgian Manufacturer RNA-TEC
Purchase expands IDT's large-scale RNA synthesis capabilities; builds presence in European markets.
Tuesday, September 19, 2006
Scientific News
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Imaging Software Could Speed Up Breast Cancer Diagnosis
Researchers use high speed optical microscopy of intact breast tissue specimens to analyze breast tissue.
A Metabolic Master Switch Underlying Human Obesity
Researchers find pathway that controls metabolism by prompting fat cells to store or burn fat.
Synthetic DNA Vaccine Against MERS Shows Promise
A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species.
How Small RNA Helps Form Memories
In a new study, a team of scientists at Scripps Florida has found that a type of genetic material called "microRNA" (miRNA) plays surprisingly different roles in the formation of memory in animal models.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!